Circulating Aminoterminal Propeptide of Type III Procollagen as a Biomarker of Cardiovascular Events in Patients Undergoing Hemodialysis
-
- Nishimura Masato
- Cardiovascular Division, Toujinkai Satellite Clinic
-
- Tokoro Toshiko
- Department of Nephrology, Toujinkai Hospital
-
- Takatani Toru
- Department of Nephrology, Toujinkai Hospital
-
- Sato Nodoka
- Department of Urology, Toujinkai Hospital
-
- Hashimoto Tetsuya
- Department of Urology, Toujinkai Hospital
-
- Kobayashi Hiroyuki
- Department of Urology, Toujinkai Hospital
-
- Ono Toshihiko
- Department of Urology, Toujinkai Hospital
この論文をさがす
抄録
<p>Aim: Type Ⅲ collagen abundantly exists in the cardiovascular system, including the aorta and heart. We prospectively investigated whether serum levels of aminoterminal propeptide of type Ⅲ procollagen (PⅢNP), a circulating biomarker of cardiovascular fibrosis, could predict cardiovascular events in patients undergoing hemodialysis.</p><p>Methods: Serum PⅢNP concentrations were measured in 244 patients undergoing maintenance hemodialysis (men, 126; women, 118; mean age, 64±11 years; dialysis duration, 11.5±7.8 years) by immunoradiometric assay in February 2005. The endpoint was cardiovascular events, and the patients were followed up until the endpoint was reached, or until January 31, 2011.</p><p>Results: During the follow-up for 4.7±1.8 years, cardiovascular events occurred in 78 (30.3%) of 244 patients. Stepwise Cox hazard analysis revealed that cardiovascular events were associated with increased serum PⅢNP concentration (1 U/mL; hazard ratio, 1.616; P=0.0001). The median serum PⅢNP concentrations were higher in patients with cardiovascular events than in those without (2.30±0.19 U/mL vs 1.30±0.03 U/mL; P＜0.0001). When the patients were assigned to subgroups based on serum PⅢNP cut-off value for cardiovascular events of 1.75 U/mL, defined by receiver operating characteristic analysis, cardiovascular event-free survival rates at 5 years were lower (P=0.0001) in the subgroup of serum PⅢNP ≥1.75 U/mL than in that of serum PⅢNP ＜1.75 U/mL (31.9% vs 88.2%).</p><p>Conclusions: Serum PⅢNP could be a new biomarker for predicting the cardiovascular events in patients undergoing hemodialysis.</p>
収録刊行物
-
- Ｊｏｕｒｎａｌ ｏｆ Ａｔｈｅｒｏｓｃｌｅｒｏｓｉｓ ａｎｄ Ｔｈｒｏｍｂｏｓｉｓ
-
Ｊｏｕｒｎａｌ ｏｆ Ａｔｈｅｒｏｓｃｌｅｒｏｓｉｓ ａｎｄ Ｔｈｒｏｍｂｏｓｉｓ 26 (4), 340-350, 2019-04-01
一般社団法人 日本動脈硬化学会